Lilly's Zepbound Gains FDA Approval for Treating Obstructive Sleep Apnea and Obesity

The FDA has approved Eli Lilly's drug Zepbound for the treatment of obstructive sleep apnea (OSA) in adults suffering from obesity, marking a significant breakthrough as it becomes the first prescription medication authorized for this condition[1][2]. This approval was granted following the promising outcomes of the SURMOUNT-OSA Phase III trial, where it demonstrated a notable 62.8% reduction in the apnea-hypopnea index, a primary measure of OSA severity[1][2]. Zepbound, which is a dual GIP/GLP-1 receptor agonist, has shown considerable effectiveness in reducing sleep apnea symptoms while also facilitating weight loss for patients[2].